IGF-1 DES is strictly for laboratory research and is commonly employed in the following investigational areas:

Myoblast Proliferation & Acute Hypertrophy Models

IGF-1 DES is utilized as a highly potent mitogen in skeletal muscle models. Because it remains unbound by IGFBPs that are heavily secreted by damaged or inflamed tissues, researchers employ it to study the rapid activation and proliferation of satellite cells (myoblasts) following mechanically induced microlesions.

Cellular Bioavailability Assays

In vitro studies utilize IGF-1 DES to map the inhibitory role of endogenous IGFBPs. By comparing the cellular growth response of native IGF-1 against the unbound DES analogue in various cell lines (such as gastric cancer cells), researchers can quantify the specific regulatory impact of carrier proteins on tissue expansion.

Neuroprotection and Neuromodulation

Research investigating central nervous system (CNS) dynamics employs IGF-1 DES to study transport kinetics and neuroprotective pathways across the blood-brain barrier (BBB). Assays assess its ability to stimulate synaptic maturation markers independent of peripheral binding proteins.

Pathway / Mechanistic Context

The primary mechanism of action for IGF-1 DES in research settings revolves around the acute, uninhibited activation of the IGF-1 receptor.

• Receptor Activation: IGF-1 DES acts as an unbound agonist at the IGF-1R, inducing a conformational change that triggers autophosphorylation of the intracellular tyrosine kinase domains.
• Signal Transduction: This binding event rapidly activates the Phosphoinositide 3-kinase (PI3K)/AKT and the Ras-Mitogen-Activated Protein Kinase (MAPK/ERK) cascades.
• Resulting Flux: Due to the absence of IGFBP buffering, IGF-1 DES induces a rapid, concentrated spike in PI3K/AKT and MAPK/ERK signaling. This cascade acutely inhibits apoptotic pathways and drives a swift, potent mitogenic response, forcing accelerated cellular division and protein synthesis before the peptide is metabolically degraded.

Preclinical Research Summary

Published preclinical literature documents investigations of IGF-1 DES across multiple experimental models:

• Bioavailability and Potency: In vitro cellular proliferation assays consistently demonstrate that IGF-1 DES is significantly more potent at stimulating cell growth than equivalent concentrations of native IGF-1, entirely due to its ability to evade sequestration by cell-secreted IGFBPs.
• Pharmacokinetics: In vivo neurobiological models show that while IGF-1 DES possesses similar biological activity to native IGF-1 at the receptor level, its lack of protein binding results in a much shorter circulatory half-life and altered transport kinetics across the blood-brain barrier.
• Synaptic Maturation: Data from CNS assays indicate that the truncated peptide functions as an active metabolite with distinct neuroprotective effects, positively regulating excitatory synaptic markers such as synapsin 1 and post-synaptic density 95 (PSD-95).

Form & Analytical Testing

This material is produced via robust chemical synthesis and supplied as a lyophilized (freeze-dried) powder.

• Lyophilization: Removes water content under vacuum to maintain compound integrity and extend shelf-life.
• Identity Verification: Each lot undergoes Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the ≥99% purity standard required for reproducible research data.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• Pan, W., Kastin, A. J., et al. (2000). Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. Neuroendocrinology, 72(3), 171-178. https://doi.org/10.1159/000054584
• Vashi, N., et al. (2016). Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Childhood-Onset Neurodevelopmental Disorders. Frontiers in Neuroscience, 10, 450. https://doi.org/10.3389/fnins.2016.00450
• Guo, Y. S., et al. (1995). Insulinlike growth factor-binding protein modulates the growth response to insulinlike growth factor 1 by human gastric cancer cells. Gastroenterology, 108(4), 993-1004.https://pubmed.ncbi.nlm.nih.gov/7684715/
• Guenther, A., et al. (2008). Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 22(6), 871-881. https://doi.org/10.1002/rcm.3444

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.